US FDA: $1bn needed to cover 'Cures' costs
This article was originally published in SRA
The US Food and Drug Administration has estimated it would cost about $1bn to cover its costs for implementing the provisions in the 21st Century Cures Act, which the House Energy and Commerce Committee started on 19 May to mark up – the point at which amendments will be added, or not, before a vote is taken on whether to move the bill to the full chamber for consideration1.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.